Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31502313 | 0.98 | SLC6A4 (0.57) | SLC6A4MAOASLC6A2SLC6A3ADRB2 | |
| Hydrochloric Acid SCHEMBL7628639 | 0.98 | SLC6A4 (0.57) | SLC6A4MAOASLC6A2SLC6A3ADRB2 | |
| Hydrochloric Acid SCHEMBL31502318 | 0.98 | SLC6A4 (0.57) | SLC6A4MAOASLC6A2SLC6A3ADRB2 | |
| SCHEMBL27230147 | 0.88 | ACACB (0.55) | SLC6A4MAOASLC6A2SLC6A3ADRB2 | |
| SCHEMBL27207792 | 0.88 | ACACB (0.55) | SLC6A4MAOASLC6A2SLC6A3ADRB2 | |
| SCHEMBL10408711 | 0.82 | ADRB2 (0.54) | SLC6A4MAOASLC6A2SLC6A3ADRB2 | |
| SCHEMBL1314596 | 0.81 | ADRB2 (0.72) | ADRB2PDE2A | |
| SCHEMBL4861453 | 0.79 | SLC6A4 (0.53) | SLC6A4MAOASLC6A2SLC6A3ADRB2 | |
| SCHEMBL4556108 | 0.79 | SLC6A4 (0.52) | SLC6A4MAOASLC6A2SLC6A3AKR1C3 | |
| SCHEMBL19382926 | 0.78 | SLC6A4 (0.57) | SLC6A4MAOASLC6A2SLC6A3AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-10-12 | — | — | US | disclosed |
| EP-2888242-B1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9346794-B1 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-20160130265-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20140057926-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-5280025-A | Aralkylaminopyrimidine derivative, and chemical for controlling noxious organisms containing the same | UBE INDUSTRIES, LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| EP-0543402-A1 | Aralkylaminopyrimidine derivative, method for preparing the same and chemical for controlling noxious organisms containing the same | UBE INDUSTRIES, LTD. (JP) | 1993-05-26 | — | — | EP | disclosed |
| EP-0443560-A2 | HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | disclosed |
| EP-0424125-A2 | Aralkylamine derivatives, preparation method thereof and fungicides containing the same | UBE INDUSTRIES, LTD. (JP) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057926-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, SERPINB6 | SLC6A4 3279/4885MAOA 332/4885SLC6A2 4018/4885 |
| US-20160130265-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, SERPINB6 | SLC6A4 3279/4885MAOA 332/4885SLC6A2 4018/4885 |
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | ENY2, ENO1, IDH1 | SLC6A4 3783/4885MAOA 601/4885SLC6A2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.